Literature DB >> 31515554

Are we AKT-ually getting closer to making targeted therapy successful in breast cancer brain metastases?

Nazanin Majd1, Shiao-Pei Weathers1, John de Groot1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31515554      PMCID： PMC6827831          DOI： 10.1093/neuonc/noz177

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  12 in total

1.  Epidemiology of brain metastases.

Authors:  Lakshmi Nayak; Eudocia Quant Lee; Patrick Y Wen
Journal:  Curr Oncol Rep       Date:  2012-02       Impact factor: 5.075

2.  Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases.

Authors:  Franziska Maria Ippen; Julia Katharina Grosch; Megha Subramanian; Benjamin Macfarlane Kuter; Bianca M Liederer; Emile G Plise; Joana Liliana Mora; Naema Nayyar; Stephen Paul Schmidt; Anita Giobbie-Hurder; Maria Martinez-Lage; Scott L Carter; Daniel P Cahill; Hiroaki Wakimoto; Priscilla Kaliopi Brastianos
Journal:  Neuro Oncol       Date:  2019-11-04       Impact factor: 12.300

3.  Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.

Authors:  Michael A Davies; Philippe Saiag; Caroline Robert; Jean-Jacques Grob; Keith T Flaherty; Ana Arance; Vanna Chiarion-Sileni; Luc Thomas; Thierry Lesimple; Laurent Mortier; Stergios J Moschos; David Hogg; Iván Márquez-Rodas; Michele Del Vecchio; Céleste Lebbé; Nicolas Meyer; Ying Zhang; Yingjie Huang; Bijoyesh Mookerjee; Georgina V Long
Journal:  Lancet Oncol       Date:  2017-06-04       Impact factor: 41.316

4.  The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA-Mutant Breast Cancer Brain Metastases.

Authors:  Franziska M Ippen; Christopher A Alvarez-Breckenridge; Benjamin M Kuter; Alexandria L Fink; Ivanna V Bihun; Matthew Lastrapes; Tristan Penson; Stephen P Schmidt; Gregory R Wojtkiewicz; Jianfang Ning; Megha Subramanian; Anita Giobbie-Hurder; Maria Martinez-Lage; Scott L Carter; Daniel P Cahill; Hiroaki Wakimoto; Priscilla K Brastianos
Journal:  Clin Cancer Res       Date:  2019-02-22       Impact factor: 12.531

5.  Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target.

Authors:  Guo Chen; Nitin Chakravarti; Kimberly Aardalen; Alexander J Lazar; Michael T Tetzlaff; Bradley Wubbenhorst; Sang-Bae Kim; Scott Kopetz; Alicia A Ledoux; Y N Vashisht Gopal; Cristiano Goncalves Pereira; Wanleng Deng; Ju-Seog Lee; Katherine L Nathanson; Kenneth D Aldape; Victor G Prieto; Darrin Stuart; Michael A Davies
Journal:  Clin Cancer Res       Date:  2014-05-06       Impact factor: 12.531

6.  Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models.

Authors:  Jie Lin; Deepak Sampath; Michelle A Nannini; Brian B Lee; Michael Degtyarev; Jason Oeh; Heidi Savage; Zhengyu Guan; Rebecca Hong; Robert Kassees; Leslie B Lee; Tyler Risom; Stefan Gross; Bianca M Liederer; Hartmut Koeppen; Nicholas J Skelton; Jeffrey J Wallin; Marcia Belvin; Elizabeth Punnoose; Lori S Friedman; Kui Lin
Journal:  Clin Cancer Res       Date:  2013-01-03       Impact factor: 12.531

7.  Factors influencing the CNS distribution of a novel MEK-1/2 inhibitor: implications for combination therapy for melanoma brain metastases.

Authors:  Shruthi Vaidhyanathan; Rajendar K Mittapalli; Jann N Sarkaria; William F Elmquist
Journal:  Drug Metab Dispos       Date:  2014-05-29       Impact factor: 3.922

8.  Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets.

Authors:  Priscilla K Brastianos; Scott L Carter; Gad Getz; William C Hahn; Sandro Santagata; Daniel P Cahill; Amaro Taylor-Weiner; Robert T Jones; Eliezer M Van Allen; Michael S Lawrence; Peleg M Horowitz; Kristian Cibulskis; Keith L Ligon; Josep Tabernero; Joan Seoane; Elena Martinez-Saez; William T Curry; Ian F Dunn; Sun Ha Paek; Sung-Hye Park; Aaron McKenna; Aaron Chevalier; Mara Rosenberg; Frederick G Barker; Corey M Gill; Paul Van Hummelen; Aaron R Thorner; Bruce E Johnson; Mai P Hoang; Toni K Choueiri; Sabina Signoretti; Carrie Sougnez; Michael S Rabin; Nancy U Lin; Eric P Winer; Anat Stemmer-Rachamimov; Matthew Meyerson; Levi Garraway; Stacey Gabriel; Eric S Lander; Rameen Beroukhim; Tracy T Batchelor; Jose Baselga; David N Louis
Journal:  Cancer Discov       Date:  2015-09-26       Impact factor: 39.397

9.  Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.

Authors:  Thomas Bachelot; Gilles Romieu; Mario Campone; Véronique Diéras; Claire Cropet; Florence Dalenc; Marta Jimenez; Emilie Le Rhun; Jean-Yves Pierga; Anthony Gonçalves; Marianne Leheurteur; Julien Domont; Maya Gutierrez; Hervé Curé; Jean-Marc Ferrero; Catherine Labbe-Devilliers
Journal:  Lancet Oncol       Date:  2012-11-02       Impact factor: 41.316

10.  Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer.

Authors:  Ji Yun Lee; Kyunghee Park; Sung Hee Lim; Hae Su Kim; Kwai Han Yoo; Ki Sun Jung; Haa-Na Song; Mineui Hong; In-Gu Do; TaeJin Ahn; Se Kyung Lee; Soo Youn Bae; Seok Won Kim; Jeong Eon Lee; Seok Jin Nam; Duk-Hwan Kim; Hae Hyun Jung; Ji-Yeon Kim; Jin Seok Ahn; Young-Hyuck Im; Yeon Hee Park
Journal:  Oncotarget       Date:  2015-12-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.